On October 23, whale positions on Hyperliquid totaled $8.251 billion, with short positions making up 53.78% of the largest accounts, indicating a bearish market sentiment. Shorts held $4.437 billion, while longs held $3.814 billion, resulting in a long-to-short ratio of 0.86. Despite the bearish skew, longs showed a profit of $159 million, whereas shorts faced a $119 million loss. Notably, one address held a 5x cross-margin short in Ether at $2,322.73, currently showing an unrealized loss of $7.18 million. This snapshot highlights the current positioning and sentiment among large traders on Hyperliquid.
Hyperliquid whale positions reached $8.25 billion, with shorts leading at 53.78%. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 24, 2026 01:31 WIB: 43 of 50 major cryptocurrencies rose today. Notable movers include BCH at Rp5.148.451 (+4.58%), ATOM at Rp31.868 (+3.75%), and LUNC at Rp0,841 (+3.57%).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
